NOAC-Drug Interactions Linked to Increased Bleeding NOAC-Drug Interactions Linked to Increased Bleeding

Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin was associated with increased risk for major bleeding compared with the use of NOACs alone in a new study.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Related Links:

Fascinating but unfortunate case: Carotid Blowout Syndrome [Oncology] Patient in late 40s diagnosed with SCC. Surgical resection incomplete due to bleeding complications (not communicated well). Pt receives 60Gy over 30 treatment days. Patient ultimately dies of carotid blowout syndrome. Sues the hospital, asks for>30 million to settle the case. Patient was highly-paid insurance executive. Exact settlement is confidential but likely was in the low 8 figure range.
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Radiation Oncology Source Type: forums
ConclusionsThe present analysis suggests that fondaparinux is safer than UFH in the management of OHCA due to AMI by reducing early bleeding complications at one month.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionsIn SR patients with CAD and HF, the rates of MI and stroke associated with rivaroxaban combined with APT were lower than those associated with APT alone, and the two treatments had similar rates of all-cause death and major bleeding.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conditions:   Coronary Artery Disease;   Atrial Fibrillation Intervention:   Sponsor:   Boehringer Ingelheim Not yet recruiting
Source: - Category: Research Source Type: clinical trials
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety,...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
CONCLUSION: Har Gabur operated in a cell-state specific manner in vivo without inducing adverse effects in normal mice. Importantly, GO was identified as the main active ingredient of Har Gabur for gastric ulcers.PMID:34544338 | DOI:10.2174/1567201818666210920101848
Source: Current Drug Delivery - Category: Drugs & Pharmacology Authors: Source Type: research
Docetaxel is a taxane, which is a class of chemotherapy agent used in the treatment of multiple malignancies. It is known to have gastrointestinal side effects which can range from mild symptoms such as nausea and diarrhea to more severe complications such as neutropenic enterocolitis. In the current literature, taxanes have not been described to cause upper gastrointestinal bleeding and melena. Here, we present a case of a 54-year-old woman with breast cancer who developed dizziness, fatigue, and melena after receiving chemotherapy. Esophagogastroduodenoscopy revealed diffuse gastric erosions as well as ulceration and lin...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
AbstractIntroductionThe effect of valve type on outcomes in transfemoral transcatheter aortic valve replacement (TF-TAVR) has recently been subject of debate. We investigate outcomes of patients treated with balloon-expanding (BE) vs. self-expanding (SE) valves in in a cohort of all these procedures performed in Germany in 2018.MethodsAll patients receiving TF-TAVR with either BE (N = 9,882) or SE (N = 7,413) valves in Germany in 2018 were identified. In-hospital outcomes were analyzed for the endpoints in-hospital mortality, major bleeding, stroke, acute kidney injury, postoperative delirium, p...
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
ConclusionsPre-existing OAC is protective in COVID-19, irrespective of anticoagulation regime during hospital stay and independent of the stage and course of disease.Graphic abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
In this study, we examined patients' access to hemophilia A (HemA) treatments across a set of large commercial health plans.Objective: To examine variation in health plans' coverage policies for HemA treatments.Methods: We reviewed HemA treatment coverage policies (current as of August 2019) issued by 17 commercial health plans primarily using the Tufts Medical Center Specialty Drug Evidence and Coverage Database. We categorized policies as: covered without conditions (coverage consistent with the FDA label); covered with conditions (conditions on coverage beyond the FDA label); broader coverage (coverage for a broader pat...
Source: Journal of Medical Economics - Category: Health Management Authors: Source Type: research
More News: Amiodarone | Bleeding | Brain | Fluconazole | Health | Neurology | Neurosurgery | Phenytoin | Study